Fibroblast Growth Factor 23 as a Therapeutic Target

Authors

  • Fan Li, MD, MS Division of Nephrology, Department of Medicine, the University of Tennessee Health Science Center, Memphis,TN, 38165, USA
  • Zhousheng Xiao, MD, PhD Division of Nephrology, Department of Medicine, the University of Tennessee Health Science Center, Memphis,TN, 38165, USA

DOI:

https://doi.org/10.17140/NPOJ-4-118

Keywords:

antagonist, fibroblast

Abstract

This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease
conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibroblast growth factor receptors
(FGFR) tyrosine kinase inhibitor, FGF-23 antibody, FGF-23 C-terminal peptide, CYP24A1 inhibitor, and FGF-23 antagonist. We
also update the advantages and disadvantages of targeting upstream and downstream molecules in FGF-23 signaling pathways.

References

Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003; 18:1227-1234. doi: 10.1359/jbmr.2003.18.7.1227

Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000; 277: 494-498. doi: 10.1006/bbrc.2000.3696

Liu S, Gupta A, Quarles LD. Emerging role of fibroblast growth factor-23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens. 2007; 16: 329-335. doi: 10.1097/ MNH.0b013e3281ca6ffd

Quarles LD. The bone and beyond: ‘Dem bones’ are made for more than walking. Nat Med. 2011; 17: 428-430. doi: 10.1038/ nm0411-428

Faul C, Amaral AP, Oskouei B, et al. FGF-23 induces left ventricular hypertrophy, J Clin Invest. 2011; 121: 393-408. doi: 10.1172/JCI46122

Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor-23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-592. doi: 10.1056/NEJMoa0706130

Olauson H, Larsson TE. FGF23 and Klotho in chronic kidney disease. Curr Opin Nephrol Hypertens. 2013; 22: 397-404. doi: 10.1097/MNH.0b013e32836213ee

Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab. 2003; 285: e1-e9. doi: 10.1152/ajpendo.00016.2003

Mackenzie NC, Zhu D, Milne EM, et al. Altered bone development and an increase in FGF-23 expression in Enpp1(-/-) mice. PLoS One. 2012; 7: e32177. doi: 10.1371/journal. pone.0032177

Han X, Li L, Yang J, King G, Xiao Z, Quarles LD. Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2 D in macrophages. FEBS Lett. 2016; 590: 53-67. doi: 10.1002/1873- 3468.12040

Han X, Xiao Z, Quarles LD. Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J Biol Chem. 2015; 290: 10447-10459. doi: 10.1074/jbc. M114.609230

Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor-23 expression but not degradation by PHEX. J Biol Chem. 2003; 278: 37419-37426. doi: 10.1074/jbc.M304544200

Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf-23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006; 291: E38-E49. doi: 10.1152/ajpendo.00008.2006

Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD. Pathogenic role of Fgf-23 in Dmp1-null mice. Am J Physiol Endocrinol Metab. 2008; 295: E254-E261. doi: 10.1152/ajpendo.90201.2008

Wang X, Wang S, Li C, et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS genet. 2012; 8: e1002708. doi: 10.1371/journal.pgen.1002708

Martin A, Liu S, David V, et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf-23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 2011; 25: 2551-2562. doi: 10.1096/ fj.10-177816

Xiao Z, Huang J, Cao L, Liang Y, Han X, Quarles LD. Osteocyte-specific deletion of Fgfr1 suppresses FGF-23. PLoS One. 2014; 9: e104154. doi: 10.1371/journal.pone.0104154

Zhang Q, Doucet M, Tomlinson RE, et al. The hypoxia-inducible factor-1alpha activates ectopic production of fibroblast growth factor-23 in tumor-induced osteomalacia. Bone Res. 2016; 4: 16011. doi: 10.1038/boneres.2016.11

Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38: 1310-1315. doi: 10.1038/ng1905

Wang X., Wang S, Li C, et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet. 2012; 8: e1002708. doi: 10.1371/journal.pgen.1002708

Whyte MP, McAlister WH, Fallon MD, et al. Raine syndrome (OMIM #259775), caused by FAM20C mutation, is congenital sclerosing osteomalacia with cerebral calcification (OMIM 259660). J Bone Miner Res. 2016; 32: 757-769. doi: 10.1002/jbmr.3034

Oya K, Ishida K, Nishida T, et al. Immunohistochemical analysis of dentin matrix protein 1 (DMP1) phosphorylation by Fam20C in bone: Implications for the induction of biomineralization. Histochem Cell Biol. 2016; 147: 341-351. doi: 10.1007/s00418-016- 1490-z

Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001; 98: 6500-6505. doi: 10.1073/pnas.101545198

Fukumoto S. Yamashita T. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens. 2002; 11: 385-389. doi: 10.1097/00041552-200207000-00003

White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001; 86: 497-500. doi: 10.1210/jcem.86.2.7408

Komaba H, Fukagawa M. The role of FGF23 in CKD--with or without Klotho. Nat Rev Nephrol. 2012; 8: 484-490. doi: 10.1038/ nrneph.2012.116 Systematic Review | Volume 4 | issue 1|

Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest. 2003; 112: 642-646. doi: 10.1172/JCI200319687

Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119: 2545-2552. doi: 10.1161/ CIRCULATIONAHA.108.844506

Isakova T, Xie H, Yang W, et al. Fibroblast growth factor-23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305: 2432-2439. doi: 10.1001/jama.2011.826

Hsu HJ, Wu MS. Fibroblast growth factor-23: A possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009; 337: 116-122. doi: 10.1097/MAJ.0b013e3181815498

Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: Associated factors and survival consequences. Nephrol Dial Transplant. 2009; 24: 948-955. doi: 10.1093/ndt/gfn571

Munoz Mendoza J, Isakova T, Ricardo AC, et al. Fibroblast growth factor-23 and Inflammation in CKD. Clin J Am Soc Nephrol. 2012; 7: 1155-1162. doi: 10.2215/CJN.13281211

Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutierrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One. 2015; 10: e0122885. doi: 10.1371/journal.pone.0122885

Wöhrle S, Henninger C, Bonny O, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013; 28: 899-911. doi: 10.1002/jbmr.1810

Wöhrle S, Bonny O, Beluch N, et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011; 26: 2486-2497. doi: 10.1002/jbmr.478

Bai X, Miao D, Xiao S, et al. CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest. 2016; 126: 667-680. doi: 10.1172/JCI81928

Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia, J Clin Invest. 2014; 124: 1587-1597. doi: 10.1172/JCI72829

Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest. 2012; 122: 2543-2553. doi: 10.1172/JCI61405

Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2010; 107: Systematic Review | Volume 4 | Number 1| Xiao Z et al 407-412. doi: 10.1073/pnas.090200610

Johnson K, Levine K, Sergi J, et al. Therapeutic effects of FGF23 c-tail Fc in a murine preclinical model of X-linked hypophosphatemia via the selective modulation of phosphate reabsorption. J Bone Miner Res. 2017; 32: 2062-2073. doi: 10.1002/ jbmr.3197

Xiao Z, Riccardi D, Velazquez HA, et al. A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia. Sci Signal. 2016; 9: ra113. doi: 10.1126/scisignal.aaf5034

Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444: 770-774. doi: 10.1038/nature05315

White KE, Cabral JM, Davis SI, et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet. 2005; 76: 361-367. doi: 10.1086/427956

Herbert C, Schieborr U, Saxena K, et al. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell. 2013; 23: 489-501. doi: 10.1016/j.ccr.2013.02.018

Herbert C, Schieborr U, Saxena K, et al. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell. 2016; 30: 176-178. doi: 10.1016/j.ccell.2016.06.015

Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009; 24: 1879-1888. doi: 10.1359/jbmr.090509

Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation. 2015; 132: 27-39. doi: 10.1161/ CIRCULATIONAHA.114.013876

Murphy D, McCulloch CE, Lin F, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med. 2016; 165: 473-481. doi: 10.7326/M16-0273

Bai XY, Miao D, Goltzman D, Karaplis AC. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem. 2003; 278: 9843-9849. doi: 10.1074/ jbc.M210490200

Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004; 145: 5269-5279. doi: 10.1210/en.2004-0233

Beck L, Soumounou Y, Martel J, et al. Pex/PEX tissue distribution and evidence for a deletion in the 3’ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest. 1997; 99: 1200-1209. doi: 10.1172/JCI119276

Otvos L, Wade JD. Current challenges in peptide-based drug discovery. Front Chem. 2014; 2: 62 doi: 10.3389/fchem.2014.00062

Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia. Bone Rep. 2017; 7: 90-97. doi: 10.1016/j. bonr.2017.09.002

Fukumoto S. Targeting fibroblast growth factor-23 signaling with antibodies and inhibitors, is there a rationale?. Front Endocrinol (Lausanne). 2018; 9: 48. doi: 10.3389/fendo.2018.00048

Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest. 2007; 117: 2684-2691. doi: 10.1172/JCI31330

Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004; 36: 579-581. doi: 10.1038/ng1358

Downloads

Published

2018-10-29

How to Cite

Fan Li, MD, MS, & Zhousheng Xiao, MD, PhD. (2018). Fibroblast Growth Factor 23 as a Therapeutic Target. Nephrology, 16–21. https://doi.org/10.17140/NPOJ-4-118

Issue

Volume 4 Issue 1 2018

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Nephrology (NOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.

Most read articles by the same author(s)